In a recent segment of Smart Bourse, we took a deep dive into the current state of capital transactions, IPOs, and M&A activity in the European healthcare sector. 

Vincent Meunier, Healthcare Investment Banking Managing Director, shared valuable insights during the discussion and remained optimistic about a revival. Vincent emphasised the importance of IPOs, M&As and aftermarket performance as key indicators of market sentiment. 

Upcoming biotech IPOs

Vincent sees particular investor interest in oncology and rare diseases, as well as significant investments in radiopharmaceuticals. 

A renewed interest in M&A Activity 

Vincent sees particular interest in oncology and rare diseases, as well as significant investments in radiopharmaceuticals. 

“Over the last few months, there is a renewed interest in M&A for precisely these types of companies. In the field of oncology, we have seen a massive wave of investment with almost 10 billion dollars spent. Players on both sides of the Atlantic: Bristol Myers Squibb, Lilly, and in Europe, Novartis and AstraZeneca.” 

The ambitions of AstraZeneca 

AstraZeneca has spent nearly $5 billion on biotech M&A over the last six months, indicating a strategic focus on high-value areas like oncology and autoimmune diseases. This activity aligns with CEO Pascal Soriot’s ambitious revenue goal of $80 billion by 2030.

Future outlooks for the healthcare sector 

Vincent ends with a cautiously optimistic outlook for the healthcare sector, with signs of recovery and strategic shifts towards long-term management, better funding, and strengthened companies ready for public markets. 

He mentions AstraZeneca’s acquisition of biotech Amolyt Pharma as a success story, which in turn had a positive effect on their share price.

“Today, the situation has indeed changed for the better. In other words, a company in biotech or MedTech can find more funding, greater funding, and for longer periods, and therefore be strengthened in terms of management, governance, and capitalisation. By the time it goes public, the company is ready.” 

As a full-service investment bank, Bryan Garnier is uniquely positioned to share insights on both IPO and M&A dynamics and provide tailored strategic advisory services to European growth companies.

Watch the full video with English subtitles here: